A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies.
about
ErbB receptors: from oncogenes to targeted cancer therapiesHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesTrastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsEngagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activationImmunological Approaches in the Treatment of Metastasized Breast CancerTumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancerThermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection.CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast CancerInhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant.TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors.Resistance to Trastuzumab in Breast Cancer.In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development.Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its F(ab')(2) Fragment in an Immunocompetent Mouse ModelDevelopment of recombinant human polyclonal antibodies for the treatment of complex human diseases.IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.Reengineering dendritic cell-based anti-cancer vaccines.Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.Cancer therapeutic antibodies come of age: targeting minimal residual disease.Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D.The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapyPharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.Production and Quality Control of [(67)Ga]-DOTA-trastuzumab for RadioimmunoscintigraphyEndophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Preclinical evaluation of holmium-166 labeled anti-VEGF-A(Bevacizumab).HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.Optimized preparation and preliminary evaluation of [64Cu]–DOTA–trastuzumab for targeting ErbB2/Neu expression
P2860
Q24683709-A30B788F-FF21-4B6F-9915-41B306DD4645Q26822730-136E0B3E-61AE-4568-A0D7-29C6CC67F5F3Q33644305-FB71A742-7F1F-4F2E-B0B7-DD1242A8751DQ33739796-54B0BD94-C916-4215-B1EF-61A076AF4BC3Q34140043-53DCBA1A-C824-4D00-AE6A-95F11938CC5DQ34194706-79CB6069-4940-425C-85EB-86CD6ED786DCQ34221898-9C932082-4634-4F2D-AA92-E2B9F93994F4Q34570753-AB5F2FC5-724F-4697-B5EA-0806CF7113F7Q35229553-656DB7FA-043C-46D2-971C-1513AC6BCA4EQ35546950-0BF971FB-B4E3-4478-82F6-E3CE0B5A35FDQ35569418-88D83563-D3E8-4C84-82A9-909189CD7883Q35624814-3A383CFC-B689-43AC-9449-1F813A913E5AQ35684440-9FD744A4-D28A-42D2-93B1-7ED0CD52ACFDQ35733827-18670A25-2DE5-407E-B76C-7F3ADA5C0A10Q35968339-EB1E5A31-1191-41F4-ADCB-BF685792CAE8Q36318226-04290D39-5F39-45FA-8472-1BA17C0EB120Q36384017-60FAD3BC-2FFD-45F5-AC5F-B8D3C2F8E590Q36440219-7817F1C9-3BA2-4A9D-BE38-EF3973AF2DC8Q36569741-ED71ACDF-6BD1-4EA2-A999-2BC4D2614B28Q36671364-BCF80CFC-93A0-4944-A3E0-2203D8EF97D4Q36729376-2A48ADC6-8133-4D20-8CB4-D5246F6BA818Q37117664-E7433941-8206-4301-8850-DDA15B2F7361Q37118177-6BAEDF31-2F8F-4D63-8F04-265DB6801D00Q37191934-F689364D-D1C0-48C4-8EE6-B0D906CBC2ACQ37273125-941A716B-A95D-40D4-94C2-F417068E674DQ37375540-5788998C-0444-4950-9954-281D625AA4D1Q37453793-295B3840-BD17-4409-B249-4B74EF5AEB6BQ37520544-5B4F29E1-6406-45A2-94B7-FEC915E6443EQ37609942-A5C39350-F2EA-42DD-85AF-9CB33BC50878Q37639279-4F460C3E-0C80-4944-8564-1561AAEAEB92Q39110347-B57B8394-E1B7-416D-9B14-C99C164F309DQ39447473-C6E533DD-4F6D-43D1-B743-290B275EA676Q42096470-362E4689-1E74-470F-9C19-540F4DB8BADFQ42281218-739536F0-A2AD-4A5A-96B5-905B97B1C907Q47156322-B7D476BB-76B4-4C14-A2FC-64349E9857E6Q53087436-F0CE21C1-3382-46D2-9A08-71D896B0092AQ54600558-E50C3404-4D0A-4A2B-BC8B-CF1076368155Q55000376-3864BF98-FA8C-481E-9812-5E1CE9D3E20CQ57567743-02E4752B-C42C-49DA-A7B3-1687D89DF3C4
P2860
A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A comparison of the in vitro a ...... oclonal anti-Her-2 antibodies.
@en
type
label
A comparison of the in vitro a ...... oclonal anti-Her-2 antibodies.
@en
prefLabel
A comparison of the in vitro a ...... oclonal anti-Her-2 antibodies.
@en
P2093
P1476
A comparison of the in vitro a ...... oclonal anti-Her-2 antibodies.
@en
P2093
Camelia I Spiridon
Ellen S Vitetta
Sarah Guinn
P304
P356
10.1158/1078-0432.CCR-03-0549
P407
P577
2004-05-01T00:00:00Z